Sugi stock trades steadily as latest annual results highlight earnings recovery

Sugi stock reflects a stabilizing earnings picture after the Japanese drugstore group reported higher profit and continued store expansion in its latest fiscal year, giving investors updated context on margins, cash flow, and growth strategy.

Sugi Holdings Co., Ltd. (ISIN JP3397000003) operates the Sugi Pharmacy drugstore chain across Japan, and Sugi stock offers investors exposure to the country’s retail pharmacy and health-care market. In its fiscal year ended 20 February 2025, the company reported a clear earnings recovery with higher profit and continued network expansion, giving the latest snapshot of operating momentum and balance-sheet strength for shareholders.

Revenue and profit trends in fiscal 2025

According to the company’s investor information for the fiscal year ended 20 February 2025, Sugi generated consolidated revenue of approximately JPY 640 billion, reflecting mid-single-digit growth compared with the previous fiscal year’s level around JPY 610 billion. The increase in top-line sales was driven by higher prescription drug volumes, growing demand for over-the-counter health products, and the contribution of newly opened stores in key prefectures. For investors, this revenue trajectory underscores Sugi’s ability to grow on both existing and new locations.

On the earnings side, the same fiscal 2025 disclosure shows that operating income improved to roughly JPY 27 billion, up from about JPY 24 billion in the prior fiscal period. This rise in operating profit, amounting to an increase of roughly 12.5%, reflects tighter cost control, improved gross margins on core categories such as prescription pharmaceuticals and daily necessities, and better labor efficiency at the store level. Net income attributable to owners of the parent reached around JPY 18 billion in fiscal 2025, compared with approximately JPY 16 billion in fiscal 2024, adding a further layer to the earnings recovery story and providing a basis for continued shareholder returns.

Margins, cash flow, and balance sheet

The profitability profile in fiscal 2025 is also visible in margin metrics. Based on the approximate figures above, Sugi’s operating margin for the period stood close to 4.2%, compared with roughly 3.9% in the previous year, marking a modest but notable improvement in profitability despite ongoing cost pressures in logistics and energy. This margin expansion indicates that the company managed to offset higher input costs through a more favorable sales mix and disciplined expense management, an important datapoint for investors evaluating the resilience of the business model.

Cash generation has remained an additional support for Sugi’s financial position. For fiscal 2025, operating cash flow was in the region of JPY 30 billion, helping to fund continued capital expenditure on store openings and refurbishments without placing undue strain on the balance sheet. Capital expenditures for the year were around JPY 15 billion, focused on new stores, IT systems, and maintenance investments. With interest-bearing debt remaining moderate relative to total assets and equity, the company’s leverage ratio stayed comfortable by Japanese retail standards, supporting flexibility for future expansion or shareholder distributions.

Store network growth and prescriptions

Store and prescription numbers provide further insight into Sugi’s operating scale. In its fiscal 2025 data, the company reported a network of around 1,600 stores, up from approximately 1,550 locations a year earlier. This expansion of roughly 50 outlets reflects continued focus on areas with aging populations and strong demand for integrated pharmacy and daily-goods services. The pace of new openings has important implications for future growth, as each new store adds to revenue potential and prescription handling capacity.

Prescription volumes have grown alongside the store count. For fiscal 2025, total prescriptions handled were close to 43 million, compared with around 40 million in fiscal 2024, an increase in the low- to mid-single-digit range. With prescriptions generally carrying higher margins than some front-of-store categories, this growth supports the improvement in overall profitability. For long-term investors, the ability to increase prescription throughput while maintaining quality and regulatory compliance is a key differentiator in Japan’s competitive drugstore market.

Dividend and shareholder returns

Sugi has continued to return cash to shareholders through dividends. In fiscal 2025, the annual dividend came to roughly JPY 90 per share, up from about JPY 85 per share in the previous year. This increase, representing a rise of nearly 5.9%, signals confidence in the company’s cash generation and earnings outlook. The dividend payout ratio remained within a range that balances shareholder remuneration with reinvestment needs, providing a measure of stability for income-oriented investors while preserving capital for growth.

This dividend progression aligns with the broader earnings trajectory. As net income climbed from around JPY 16 billion to approximately JPY 18 billion between fiscal 2024 and fiscal 2025, the company was able to support a higher cash distribution without stretching the balance sheet. For holders of Sugi stock, the combination of growing earnings, modest margin improvement, and incremental dividend increases forms a coherent narrative of cautious but steady shareholder value creation.

Sugi Pharmacy product focus

Within Sugi’s operations, a representative focus is the Sugi Pharmacy prescription dispensing service, which sits at the heart of the company’s business model. The chain combines prescription pharmaceuticals, over-the-counter medicines, health-care products, and daily necessities under one roof, aiming to serve regular customers in local communities. In fiscal 2025, prescription-related revenue accounted for a significant portion of total sales, supporting both margins and customer loyalty.

The company’s emphasis on prescription services also aligns with demographic trends in Japan, where an aging population requires more frequent medical and pharmaceutical support. By investing in pharmacy staff training, digital prescription-handling systems, and store layouts that make it easier for patients to receive advice and medication efficiently, Sugi aims to deepen its role in community health care. For investors, the strength of this prescription-centric product and service mix is an important driver of Sugi stock’s long-term appeal.

Sugi stock and market context

Sugi Holdings Co., Ltd. is listed on the Tokyo Stock Exchange, and Sugi stock is traded in Japanese yen. As of late June 2025, the shares were quoted around JPY 4,000, placing them roughly in the middle of a 52-week range that has extended from approximately JPY 3,500 on the low side to about JPY 4,400 on the high side. This price context suggests that the market has broadly incorporated the latest earnings recovery and dividend increase into valuation, while still leaving room for investor debate on future growth and margin resilience.

With a market capitalization near JPY 260 billion as of 30 June 2025, Sugi ranks among the larger domestic drugstore and pharmacy chains in Japan. The share price evolution across the fiscal 2024 to fiscal 2025 period has been influenced by broader sector trends, including competition from other chains, the impact of regulatory developments on prescription margins, and consumer behavior in a post-pandemic environment. For international investors, the stock offers diversified exposure to Japan’s health-care retail sector, though it remains sensitive to domestic economic conditions and policy shifts.

Key data on Sugi Holdings

• Company: Sugi Holdings Co., Ltd.
• ISIN: JP3397000003
• Ticker: TSE: 7649
• Trading venue: Tokyo Stock Exchange
• Price (as of 30 June 2025, 15:00 JST): 4,000 JPY
• Market capitalization: 260 billion JPY (as of 30 June 2025)
• Sector / Industry: Consumer Staples / Drugstore and Pharmacy Retail
• Index membership: Tokyo Stock Exchange Prime Market benchmark indices